$242 Million is the total value of Essex Woodlands Management, Inc.'s 7 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BVS | BIOVENTUS | $84,677,000 | +2.6% | 12,096,702 | 0.0% | 34.99% | +2.6% | |
MDXG | MIMEDX GROUP, INC. | $67,203,000 | -17.3% | 23,415,584 | 0.0% | 27.77% | -17.3% | |
EYPT | EYEPOINT PHARMACEUTICALS INC | $33,150,000 | +0.5% | 4,190,921 | 0.0% | 13.70% | +0.5% | |
RVNC | REVANCE THERAPEUTICS INC | $12,341,000 | +95.4% | 457,085 | 0.0% | 5.10% | +95.3% | |
VERO | VENUS CONCEPT, INC. | $7,189,000 | -4.3% | 21,169,457 | 0.0% | 2.97% | -4.3% | |
MNOV | MEDICINOVA INC | $2,400,000 | -14.2% | 1,105,941 | 0.0% | 0.99% | -14.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MEDICINOVA INC | 42 | Q3 2023 | 6.5% |
REVANCE THERAPEUTICS INC | 39 | Q3 2023 | 44.6% |
AXOGEN INC | 26 | Q4 2021 | 43.3% |
ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
ABIOMED INC | 20 | Q1 2018 | 52.1% |
CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
TELA BIO, INC. | 16 | Q3 2023 | 31.5% |
VENUS CONCEPT, INC. | 16 | Q3 2023 | 21.3% |
ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
CATALYST BIOSCIENCES INC | 15 | Q1 2019 | 1.0% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-15 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.